Publications & Presentations
Publications
GT103 and Complement
Tumor-derived complement C3 overexpression in STK11-mutant lung adenocarcinoma drives tumor growth and immune checkpoint inhibitor resistance. Sora Suzuki, Bojidar Kandar, Catrina Ting, Peter Deraska, Te-An Chen, Thejaswini Giridharan, Anm Nazmul H Khan, Kristopher Attwood, Han Yu, Kayla Catalfamo, Prashant K Singh, Ryan T Bushey, Elizabeth B Gottlin, Michael J Campa, Edward F Patz, Daniel Ajona, Ruben Pio, Brahm H Segal, Edwin H Yau. April 2026.
Some Immune Systems Defeat Cancer. Could That Become a Drug? By Gina Kolata – New York Times. January 22, 2026.
A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non–small cell lung cancer. Hirva Mamdani MD, Ryan D. Gentzler MD MS, Lin Gu MS, Alberto A. Chiappori MD, Frank D. Weinberg MD, PhD, Greg Durm MD, Sarada Gurubhagavatula MD, Thomas E. Stinchcombe MD, James E. Herndon II PhD, Edward F. Patz Jr MD, Jeffrey Clarke MD. November 1, 2025.
A tumor-binding antibody with cross-reactivity to viral antigens. Michael J Campa, Elizabeth B Gottlin, Kevin Wiehe, Edward F Patz Jr. February 26, 2025.
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial. Jeffrey M Clarke, George R Simon, Hirva Mamdani, Lin Gu, James E Herndon 2nd, Thomas E Stinchcombe, Neal Ready, Jeffrey Crawford, Guru Sonpavde, Stephen Balevic, Andrew B Nixon, Michael Campa, Elizabeth B Gottlin, Huihua Li, Ruchi Saxena, You Wen He, Scott Antonia, Edward F Patz Jr. January 2, 2025.
Complement regulators as novel targets for anti-cancer therapy: A comprehensive review. Ruchi Saxena, Elizabeth B Gottlin, Michael J Campa, You-Wen He, Edward F Patz Jr. January 2025.
Promotion of an Antitumor Immune Program by a Tumor-specific, Complement-activating Antibody.
Ruchi Saxena, Ryan T. Bushey, Michael J. Campa, Elizabeth B. Gottlin, Jian Guo, Edward F. Patz, Jr, and You-Wen He. April 1, 2024.
Complement factor H: a novel innate immune checkpoint in cancer immunotherapy.
Saxena R, Gottlin EB, Campa MJ, Bushey RT, Guo J, Patz EF Jr, He YW. Frontiers in Cell and Developmental Biology. February 8, 2024.
Creation of a Favorable Antitumor Microenvironment by the Anti-Complement Factor H Antibody GT103
Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103
Prognostic significance of a complement factor H autoantibody in early stage NSCLC. Gottlin EB, Campa MJ, Gandhi R, Bushey RT, Herndon Nd JE, Patz EF Jr.Cancer Biomark. 2022 Jan 14. doi: 10.3233/CBM-210355. Online ahead of print.PMID: 35068447
Electrochemical micro-aptasensors for exosome detection
Coming together at the hinges: Therapeutic prospects of IgG3
Tumour extracellular vesicle-derived Complement Factor H promotes tumorigenesis and metastasis by inhibiting complement-dependent cytotoxicity of tumour cells. Mao X, Zhou L, Tey S, Ma A, Yeung C, Ng T, Wong S, Liu B, Fung Y, Patz EF Jr., Cao P, Gao Y, Yam J. J Extracell Vesicles. Oct/Nov 2020 Vol 10, Issue 1. doi.org/10.1002/jev2.12031.
Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody. Winkler MT, Bushey RT, Gottlin EB, Campa MJ, Guadalupe ES, Volkheimer AD, Weinberg JB, Patz EF Jr. PLoS One. 2017 Jun 28; 12(6):e0179841. doi: 10.1371/journal.pone.0179841. eCollection 2017.
A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. Bushey RT, Moody MA, Nicely NL, Haynes BF, Alam SM, Keir ST, Bentley RC, Roy Choudhury K, Gottlin EB, Campa MJ, Liao HX, Patz EF Jr. Cell Rep. 2016 May 17;15(7):1505-1513. doi: 10.1016/j.celrep.2016.04.038. Epub 2016 May 5.
Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy. Campa MJ, Gottlin EB, Bushey RT, Patz EF Jr. Cancer Immunol Res. 2015 Dec;3(12):1325-32. doi: 10.1158/2326-6066.CIR-15-0122. Epub 2015 Jul 27.
Complement factor H autoantibodies are associated with early stage NSCLC. Amornsiripanitch N, Hong S, Campa MJ, Frank MM, Gottlin EB, Patz EF Jr. Clin Cancer Res. 2010 Jun 15;16(12):3226-31. doi: 10.1158/1078-0432.CCR-10-0321. Epub 2010 Jun 1.
Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression. Wang Y, Sun SN, Liu Q, Yu YY, Guo J, Wang K, Xing BC, Zheng QF, Campa MJ, Patz EF Jr., Li SY, He YW. Cancer Discov. 2016 Sep;6(9):1022-35. doi: 10.1158/2159-8290.CD-15-1412. Epub 2016 Jun 13.
Creation of a Favorable Antitumor Microenvironment by the Anti-Complement Factor H Antibody GT103
Related publications
Do autoantibodies shape cancer immunosurveillance? Paul Bastard, Tyler Hulett, Karl Smith-Byrne, Nils Landegren, Trine H. Mogensen, Jacques Fellay, Ruth C. Travis, Jean-Laurent Casanova, Chi V. Dang, and Xin Lu. Cell. 2026 Jul 23;189(15):4525-4530. doi: 10.1016/j.cell.2026.06.021. PMID: 42492493
Novel genetic variants in HDAC2 and PPARGC1A of the CREB-binding protein pathway predict survival of non-small-cell lung cancer. Tang D, Zhao YC, Qian D, Liu H, Luo S, Patz EF Jr., Moorman PG, Su L, Shen S, Christiani DC, Glass C, Gao W, Wei Q. Mol Carcinog. 2020 Jan;59(1):104-115. doi: 10.1002/mc.23132. Epub 2019 Nov 12. PMID: 31713888
Genetic variants in RUNX3, AMD1 and MSRA in the methionine metabolic pathway and survival in nonsmall cell lung cancer patients. Chen K, Liu H, Liu Z, Luo S, Patz EF Jr., Moorman PG, Su L, Shen S, Christiani DC, Wei Q. Int J Cancer. 2019 Aug 1;145(3):621-631. doi: 10.1002/ijc.32128. Epub 2019 Feb 1. PMID:30650190
Whole Exome Sequencing of Cell-Free DNA for Early Lung Cancer: A Pilot Study to Differentiate Benign From Malignant CT-Detected Pulmonary Lesions. Tailor TD, Rao X, Campa MJ, Wang J, Gregory SG, Patz EF Jr. Front Oncol. 2019 Apr 24;9:317. doi:10.3389/fonc.2019.00317. eCollection 2019. PMID: 31069172
Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. Qian D, Liu H, Wang X, Ge J, Luo S, Patz EF Jr., Moorman PG, Su L, Shen S, Christiani DC, Wei Q. Int J Cancer. 2019 Apr 15;144(8):1867-1876. doi: 10.1002/ijc.31896. Epub 2018 Dec 8. PMID: 30259978
The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer. Gottlin EB, Bentley RC, Campa MJ, Pisetsky DS, Herndon JE 2nd, Patz EF Jr. J Thorac Oncol. 2011 Oct;6(10):1687-90. doi: 10.1097/JTO.0b013e3182217bec.
A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer. Ashton JR, Gottlin EB, Patz EF Jr., West JL, Badea CT. PLoS One. 2018 Nov 8;13(11):e0206950. doi: 10.1371/journal.pone.0206950. eCollection 2018. PMID:30408128
Sequential CT Findings in Patients With Non-small-cell Lung Cancer Receiving Nivolumab. Johnson DY, Short RG, Patz EF Jr. Clin Lung Cancer. 2018 Mar;19(2):175-180. doi: 10.1016/j.cllc.2017.10.009. Epub 2017 Oct 28. PMID: 29153896
PRESENTATIONS
10th Complement-Based Drug Development Summit. December 8-10, 2026 | Boston, MA
20th European Meeting on Complement in Human Disease (EMCHD26). 1st – 5th September 2026 in Cardiff, Wales.
European Society For Medical Oncology. 2026.
20th European Meeting on Complement in Human Disease (EMCHD26). 1st – 5th September 2026 in Cardiff, Wales.
Antibodies and complement : B cells, antibodies, complement functions & therapeutics. May 26-30, 2025
8th Complement-Based Drug Development Summit. December 10-12, 2024
Society for Immunotherapy of Cancer (SITC) 2024. November 6-10, 2024
International Complement Society 5th Virtual Symposium: Complement and Cancer. November 7, 2024
PEGS Boston (Protein Engineering Summit) Boston, Boston, MA May, 2017
Fleischner Society Annual Meeting, Boston, MA June 2017
IASLC Annual Meeting, Yokohama, Japan October 2017
University of Colorado, Cancer Biology Program, Denver Colorado March, 2018
Stanford University, Canary Center at Stanford, Palo Alto, California May, 2018
Fleischner Society Annual Meeting, Paris France May, 2019
LUNGevity Scientific Retreat. Washington, DC October 2019
Hillman Cancer Center, UPMC, Pittsburgh, PA November, 2019
Cambridge Healthtech Institute Emerging Targets for Immunomodulatory Antibodies, 9th Annual Immuno-Oncology Summit. Boston, MA Oct 2021
Complement-based Drug Development 2021, Oct 2021
P53.05 Inhibition of Tumor Cell Intrinsic Complement Regulatory Proteins Leads to Decreased Tumor Growth in a Mouse Model of NSCLC, 2021 World Conference on Lung Cancer (View Abstract)
Complement as a Natural Adjuvant to Promote Anti-Tumor Immunity in Cancer Therapy, Edward (Ned) F. Patz, Jr., M.D., CEO – Grid Therapeutics, LLC. Presenting at Complement-based Drug Development Summit 2022, September, 2022
Development of Novel Immuno-Oncology Targets from Host B Cells: The Other Side of Autoimmunity, Edward (Ned) Patz, MD, CEO, Grid Therapeutics; Professor, Radiology, Duke University. Presenting at Immuno-Oncology Summit – October, 2022 Boston
Interim Results from a Phase IB, First-in-Human Study of a Novel Complement Factor H Inhibitor (GT103) in Patients with Refractory Non-Small Cell Lung Cancer (NSCLC). Presenting at SITC meeting in Boston, November 2022
Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC), Jeffrey Clarke. 2023 ASCO Annual Meeting